Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that necrosis-inducing peptide P16 kills human glioblastoma cancer cells and primary human hepatoma or renal cancer cells isolated from patients who had not responded to standard treatments.
|
31206614 |
2019 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We treated human glioblastoma cells with BP and found a dose-dependent decrease in human telomerase reverse transcriptase (hTERT) mRNA expression and a concomitant increase in p16 and p21 expression.
|
21553143 |
2011 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the combination of p16 and p21(CIP1) (p21-S154A) peptides dramatically suppressed the growth of glioblastoma line Gli36DeltaEGFR, which carries a missense mutation in p53, by >97% after 120 h. Significantly, our murine brain tumor model for dual-peptide delivery showed a substantial average survival enhancement (P < 0.0001) for peptide-treated mice.
|
18566217 |
2008 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The U251 glioblastoma and a glioblastoma xenograft cell line transduced with a recombinant replication-defective adenovirus vector containing the cDNA of wild-type p16 and antisense RNA of uPAR significantly inhibited human mammary epithelial cell capillary formation and vascular endothelial growth factor (VEGF) expression.
|
17273768 |
2007 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present case is unusual in four aspects: (i) it arose from a low-grade ganglioglioma in the absence of previous radiation or chemotherapy, which is the fourth reported case; (ii) the original tumor showed a high proliferative index on flow cytometry but a low Ki-67 labeling index, implying that the application of flow cytometry might play a certain role in predicting biological and clinical behavior of low grade gangliogliomas; (iii) p53 mutation and deletion appeared in the secondary glioblastoma, which was not shown in the original well-differentiated ganglioglioma; and (iv) the transformed glioblastoma showed p16 inactivation detected by methylation and deletion, which are relatively uncommon genetic events in secondary glioblastomas.
|
14629754 |
2003 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The bicistronic construct (Ad-uPAR/p16)-infected glioblastoma cell lines had significantly lower levels of uPAR and higher levels of p16 than controls.
|
11791179 |
2002 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of this study suggest that p16 homozygous deletion is a significant unfavorable prognostic factor in male patients with GBM.
|
12005388 |
2002 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of pRB following p16 expression might severely limit the potential benefit of p16 gene therapy for glioblastoma.
|
12416540 |
2002 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ.
|
11549271 |
2001 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All but 4 tumors (84%) showed alterations known to be preferentially involved in the progression of astrocytic tumors to GBM, such as EGFR amplification (44%), P16 deletion (48%), LOH on 10q (64%), PTEN (20%), and TP53 (24%) mutations.
|
11556543 |
2001 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the tumor suppressor p16 may exert its antitumor effects through modulation of multiple aspects of glioblastoma phenotypes, including proliferation, invasiveness, and responsiveness to extracellular growth stimuli.
|
11908877 |
2001 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT-2 rat GBM cell line was used to investigate if the p16 gene induces dominant suppression of glioblastoma growth.
|
10720483 |
2000 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunoreactivity for p16 was absent in 56% of the GBM and 77.5% of the AA.
|
11029499 |
2000 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Including 20 additional glioblastoma-derived cell lines we detected that in 19 of the total 31 lines at least one exon was lost bringing the rate of p16 loss in the whole panel to 61%.
|
10536182 |
1999 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The human glioblastoma cell line U87MG was doubly transfected with the plasmids pVgRXR and pIND harboring the wild-type p16 gene.
|
10360478 |
1999 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have also shown the presence of heterogeneous cell populations within the glioblastoma masses based on the variety of the mutated p16 sequences.
|
10536183 |
1999 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, p16 deletions were significantly more frequent in the former (10/28; 36%) than in the latter (1/23, 4%; P = 0.0075), suggesting that this alteration constitutes an additional genetic hallmark of the primary (de novo) glioblastoma.
|
9341929 |
1997 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the target of deletion in glioblastoma multiforme includes both p15 and p16 genes.
|
7987828 |
1994 |